Agilent's Fiscal Q4 Revenues Rise 6 Percent; Bio-Analytical Measurement Grows 9 Percent | GenomeWeb
NEW YORK (GenomeWeb News) — Agilent Technologies today said fiscal fourth-quarter revenues increased 6 percent as R&D spending fell 8 percent and profit surged 508 percent.
 
Total receipts for the three months ended Sept. 30 increased to $1.33 billion from $1.25 billion year over year.
 
Revenue for the company’s Bio-Analytical Measurement segment rose 9 percent to $418 million.
 
R&D spending decreased to $155 million from $168 million year over year.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: carbapenem resistance in Enterobacteriaceae, selection against educational attainment-linked variants, and more.

Technology Review points out that a new US presidential science advisor hasn't been selected.

Researchers find that blood tests might be able to help determine severity of a concussion, Wired reports.

President-elect Donald Trump considers other candidates for director of the National Institutes of Health, Nature News reports.